AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy
Jennings, Matthew J.
Heslegrave, Amanda J.
Reilly, Mary M.
Nature Publishing Group UK
MetadataShow full item record
Kagiava, A., Karaiskos, C., Richter, J., Tryfonos, C., Jennings, M. J., Heslegrave, A. J., Sargiannidou, I., et al. (2021). AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. Gene Therapy, 28 (10-11), 659-675. https://doi.org/10.1038/s41434-021-00250-0
Funder: The Republic of Cyprus through the Research and Innovation Foundation Foundation (Project: CULTURE/BR-NE/0416/07)
Funder: Wallenberg Scholar and the fluid biomarker measurements in the lab of HZ and AJH were supported by the UK Dementia Research Institute at UCL
Abstract: Mutations in the GJB1 gene, encoding the gap junction (GJ) protein connexin32 (Cx32), cause X-linked Charcot-Marie-Tooth disease (CMT1X), an inherited demyelinating neuropathy. We developed a gene therapy approach for CMT1X using an AAV9 vector to deliver the GJB1/Cx32 gene under the myelin protein zero (Mpz) promoter for targeted expression in Schwann cells. Lumbar intrathecal injection of the AAV9-Mpz.GJB1 resulted in widespread biodistribution in the peripheral nervous system including lumbar roots, sciatic and femoral nerves, as well as in Cx32 expression in the paranodal non-compact myelin areas of myelinated fibers. A pre-, as well as post-onset treatment trial in Gjb1-null mice, demonstrated improved motor performance and sciatic nerve conduction velocities along with improved myelination and reduced inflammation in peripheral nerve tissues. Blood biomarker levels were also significantly ameliorated in treated mice. This study provides evidence that a clinically translatable AAV9-mediated gene therapy approach targeting Schwann cells could potentially treat CMT1X.
Article, /631/378/1959, /692/699/375, /631/378/2606, /692/53, /13/51, /64/110, /82/29, /101/28, article
RCUK | Medical Research Council (MRC) (MRC MR/S005021/1, MR/N025431/1)
Muscular Dystrophy Association (Muscular Dystrophy Association Inc.) (MDA510281, 603003, 480030)
Newton Fund (MR/N027302/1)
External DOI: https://doi.org/10.1038/s41434-021-00250-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330880
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com